MOUNTAIN VIEW, Calif., Feb. 18, 2011 /PRNewswire/ — MAP
Pharmaceuticals, Inc. (Nasdaq:
MAPP) today announced the appointment of Scott R. Ward as
Chairman of its Board of Directors. Steven A. Elms, the incumbent
Chairman and an original venture capital investor in the Company,
will step down from the Board of Directors after over six years of
service.
“I want to thank Steve for all his contributions to the Company
and the Board as we have grown from an early concept to a
late-stage development organization. I look forward to
working with Scott as we prepare for our first NDA submission and
potential product launch,” said Timothy S. Nelson, MAP
Pharmaceuticals’ President and Chief Executive Officer.
“Scott brings 30 years of industry and commercial experience
and his leadership will be greatly valued as the Company continues
to grow.”
“I am pleased to take on the role of Chairman of the MAP
Pharmaceuticals Board at this time, as the Company is transitioning
into a commercial organization,” said Scott R. Ward. “With the
recently announced Allergan collaboration, the Company has
established a strategic pathway for the potential commercialization
of LEVADEX for the acute treatment of migraine.”
Mr. Ward has extensive experience in the healthcare industry
including 15 years as an operating business leader, and various
roles in regulatory affairs, clinical research and business
development since he joined Medtronic, Inc. in 1981. Mr. Ward has
led the development and commercial launch of 20 significant new
products and therapies in the cardiovascular and neurological
markets.
Most recently, Mr. Ward was Senior Vice President and President
of the CardioVascular business of Medtronic which generated
approximately $3 billion in annual sales. He was responsible
for all worldwide operations of the CardioVascular sector including
the Coronary,
‘/>”/>
SOURCE
